Angel Invest Boston

Join Sal Daher's Investment Syndicate: Click to Join Jeff Behren's doctoral dissertation suggests that life science startups are not funded the way we all think. Listen to our discussion of his work and learn why he believes we have to revise what is taught to founders about raising money. Highlights: Sal Daher Welcomes Jeff Behrens Back on the Podcast to Discuss His Findings on Biotech Funding “We published papers. We had a world class SAB, and ultimately, we sold these drugs. So, during that, you'd think, "Well, we should be able to raise venture capital." We never could.” The Conventional Wisdom about How Life Science Startups Are Funded Casma Therapeutics as an Example of a Startup Born Inside a Venture Firm “There was no Lisa and Joe… There [was] no outside founders. This was born inside the venture firm.” Jeff’s Research Result: Only 8% of All Startups Follow Path of Angel Funding Then VC Funding Jeff’s Research Result: For Biotech Startups, 4.5% of those that Started with Angel Money Got VC Funding “S